An assessment of implications of adaptive licensing for pharmaceutical intellectual property and regulatory exclusivity rights in the European Union.
One of the key advantages of adaptive licensing is to align the licensing of new medicines more closely with patient needs for earlier access to beneficial treatments. From an innovators perspective ‘earlier’ market access may seem an obvious incentive to gain earlier revenue generation. This is how...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2016
|
| _version_ | 1797081750155821056 |
|---|---|
| author | Meier, A Faulkner, S Schoonderbeek, C Jong, B Kung, J Brindley, D Barker, R |
| author_facet | Meier, A Faulkner, S Schoonderbeek, C Jong, B Kung, J Brindley, D Barker, R |
| author_sort | Meier, A |
| collection | OXFORD |
| description | One of the key advantages of adaptive licensing is to align the licensing of new medicines more closely with patient needs for earlier access to beneficial treatments. From an innovators perspective ‘earlier’ market access may seem an obvious incentive to gain earlier revenue generation. This is however, offset with an ‘earlier’ start to patent protection periods- which depending on the technology, disease, population and timing of subsequent asset protection periods, can present a conflict. |
| first_indexed | 2024-03-07T01:18:24Z |
| format | Journal article |
| id | oxford-uuid:8f7e8983-ea7b-4ed7-949c-fe59ec256b2b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:18:24Z |
| publishDate | 2016 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:8f7e8983-ea7b-4ed7-949c-fe59ec256b2b2022-03-26T23:04:42ZAn assessment of implications of adaptive licensing for pharmaceutical intellectual property and regulatory exclusivity rights in the European Union.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:8f7e8983-ea7b-4ed7-949c-fe59ec256b2bEnglishSymplectic Elements at OxfordWiley2016Meier, AFaulkner, SSchoonderbeek, CJong, BKung, JBrindley, DBarker, ROne of the key advantages of adaptive licensing is to align the licensing of new medicines more closely with patient needs for earlier access to beneficial treatments. From an innovators perspective ‘earlier’ market access may seem an obvious incentive to gain earlier revenue generation. This is however, offset with an ‘earlier’ start to patent protection periods- which depending on the technology, disease, population and timing of subsequent asset protection periods, can present a conflict. |
| spellingShingle | Meier, A Faulkner, S Schoonderbeek, C Jong, B Kung, J Brindley, D Barker, R An assessment of implications of adaptive licensing for pharmaceutical intellectual property and regulatory exclusivity rights in the European Union. |
| title | An assessment of implications of adaptive licensing for pharmaceutical intellectual property and regulatory exclusivity rights in the European Union. |
| title_full | An assessment of implications of adaptive licensing for pharmaceutical intellectual property and regulatory exclusivity rights in the European Union. |
| title_fullStr | An assessment of implications of adaptive licensing for pharmaceutical intellectual property and regulatory exclusivity rights in the European Union. |
| title_full_unstemmed | An assessment of implications of adaptive licensing for pharmaceutical intellectual property and regulatory exclusivity rights in the European Union. |
| title_short | An assessment of implications of adaptive licensing for pharmaceutical intellectual property and regulatory exclusivity rights in the European Union. |
| title_sort | assessment of implications of adaptive licensing for pharmaceutical intellectual property and regulatory exclusivity rights in the european union |
| work_keys_str_mv | AT meiera anassessmentofimplicationsofadaptivelicensingforpharmaceuticalintellectualpropertyandregulatoryexclusivityrightsintheeuropeanunion AT faulkners anassessmentofimplicationsofadaptivelicensingforpharmaceuticalintellectualpropertyandregulatoryexclusivityrightsintheeuropeanunion AT schoonderbeekc anassessmentofimplicationsofadaptivelicensingforpharmaceuticalintellectualpropertyandregulatoryexclusivityrightsintheeuropeanunion AT jongb anassessmentofimplicationsofadaptivelicensingforpharmaceuticalintellectualpropertyandregulatoryexclusivityrightsintheeuropeanunion AT kungj anassessmentofimplicationsofadaptivelicensingforpharmaceuticalintellectualpropertyandregulatoryexclusivityrightsintheeuropeanunion AT brindleyd anassessmentofimplicationsofadaptivelicensingforpharmaceuticalintellectualpropertyandregulatoryexclusivityrightsintheeuropeanunion AT barkerr anassessmentofimplicationsofadaptivelicensingforpharmaceuticalintellectualpropertyandregulatoryexclusivityrightsintheeuropeanunion AT meiera assessmentofimplicationsofadaptivelicensingforpharmaceuticalintellectualpropertyandregulatoryexclusivityrightsintheeuropeanunion AT faulkners assessmentofimplicationsofadaptivelicensingforpharmaceuticalintellectualpropertyandregulatoryexclusivityrightsintheeuropeanunion AT schoonderbeekc assessmentofimplicationsofadaptivelicensingforpharmaceuticalintellectualpropertyandregulatoryexclusivityrightsintheeuropeanunion AT jongb assessmentofimplicationsofadaptivelicensingforpharmaceuticalintellectualpropertyandregulatoryexclusivityrightsintheeuropeanunion AT kungj assessmentofimplicationsofadaptivelicensingforpharmaceuticalintellectualpropertyandregulatoryexclusivityrightsintheeuropeanunion AT brindleyd assessmentofimplicationsofadaptivelicensingforpharmaceuticalintellectualpropertyandregulatoryexclusivityrightsintheeuropeanunion AT barkerr assessmentofimplicationsofadaptivelicensingforpharmaceuticalintellectualpropertyandregulatoryexclusivityrightsintheeuropeanunion |